Literature DB >> 23417376

Relapsing-remitting multiple sclerosis and chronic idiopathic neutropenia: a challenging combination.

Eva Jolanda Münzel1, Jennie Z Wimperis, Anna Williams.   

Abstract

We report the challenges of treating relapsing-remitting multiple sclerosis (MS) in a 31-year-old woman with long-standing chronic idiopathic neutropenia. The treatment with the disease-modifying therapy interferon-β was significantly complicated by a further fall in her generally low neutrophil count, to values below 0.5×10(9)/l, although this recovered rapidly when the treatment was stopped. We discuss the difficulties of balancing the risk of neutropenia with a risk of MS relapse.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23417376      PMCID: PMC3604507          DOI: 10.1136/bcr-2012-007936

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  13 in total

Review 1.  Interferon-β-1b: a review of its use in multiple sclerosis.

Authors:  Greg L Plosker
Journal:  CNS Drugs       Date:  2011-01       Impact factor: 5.749

2.  In vivo effects of interferon beta-1a on immunosuppressive cytokines in multiple sclerosis.

Authors:  R A Rudick; R M Ransohoff; J C Lee; R Peppler; M Yu; P M Mathisen; V K Tuohy
Journal:  Neurology       Date:  1998-05       Impact factor: 9.910

3.  Neurotrophic factors in relapsing remitting and secondary progressive multiple sclerosis patients during interferon beta therapy.

Authors:  Marcella Caggiula; Anna Paola Batocchi; Giovanni Frisullo; Francesco Angelucci; Agata Katia Patanella; Cristina Sancricca; Viviana Nociti; Pietro Attilio Tonali; Massimiliano Mirabella
Journal:  Clin Immunol       Date:  2005-11-07       Impact factor: 3.969

4.  Autoimmune neutropenia associated with multiple sclerosis.

Authors:  Teruhiko Kozuka; Kensuke Kojima; Kinuyo Kaneda; Katsuto Takenaka; Yasuhiro Manabe; Yasushi Hirata; Shigenori Okuma; Hironobu Toki; Mitsune Tanimoto
Journal:  Intern Med       Date:  2003-01       Impact factor: 1.271

5.  Interferon (IFN) beta acts downstream of IFN-gamma-induced class II transactivator messenger RNA accumulation to block major histocompatibility complex class II gene expression and requires the 48-kD DNA-binding protein, ISGF3-gamma.

Authors:  H T Lu; J L Riley; G T Babcock; M Huston; G R Stark; J M Boss; R M Ransohoff
Journal:  J Exp Med       Date:  1995-11-01       Impact factor: 14.307

6.  Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group.

Authors: 
Journal:  Lancet       Date:  1998-11-07       Impact factor: 79.321

7.  Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial.

Authors:  Daniel D Mikol; Frederik Barkhof; Peter Chang; Patricia K Coyle; Douglas R Jeffery; Steven R Schwid; Bettina Stubinski; Bernard M J Uitdehaag
Journal:  Lancet Neurol       Date:  2008-09-11       Impact factor: 44.182

8.  Haematological effects of interferon-beta-1a (Rebif) therapy in multiple sclerosis.

Authors:  Peter Rieckmann; Paul O'Connor; Gordon S Francis; Graham Wetherill; Enrica Alteri
Journal:  Drug Saf       Date:  2004       Impact factor: 5.606

9.  Interferon beta decreases T cell activation and interferon gamma production in multiple sclerosis.

Authors:  A Noronha; A Toscas; M A Jensen
Journal:  J Neuroimmunol       Date:  1993-07       Impact factor: 3.478

10.  250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study.

Authors:  Paul O'Connor; Massimo Filippi; Barry Arnason; Giancarlo Comi; Stuart Cook; Douglas Goodin; Hans-Peter Hartung; Douglas Jeffery; Ludwig Kappos; Francis Boateng; Vitali Filippov; Maria Groth; Volker Knappertz; Christian Kraus; Rupert Sandbrink; Christoph Pohl; Timon Bogumil; P O'Connor; M Filippi; B Arnason; S Cook; D Goodin; H-P Hartung; H-P Harung; L Kappos; D Jeffery; G Comi
Journal:  Lancet Neurol       Date:  2009-09-02       Impact factor: 44.182

View more
  1 in total

1.  Anti-inflammatory mechanisms of IFN-γ studied in experimental autoimmune encephalomyelitis reveal neutrophils as a potential target in multiple sclerosis.

Authors:  Nichole M Miller; Jun Wang; Yanping Tan; Bonnie N Dittel
Journal:  Front Neurosci       Date:  2015-08-18       Impact factor: 4.677

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.